List view / Grid view
29 May 2014 | By SMI Group
Impending patent expirations on blockbuster biologics and a volatile financial environment is causing payers to seek wider adoption of biosimilars in order to manage growing healthcare costs...
29 May 2014 | By SMI Group
Companies are realizing that their own internal R&D groups alone are not enough and as pharma groups slash their internal R&D projects...
29 May 2014 | By GTCBio
George Weinstock, Professor and Associate Director at The Jackson Laboratory for Genomic Medicine to give a keynote presentation on “Exploring the Role of the Microbiome in Disease”...
29 May 2014 | By GTCBio
John Herrmann, Chief Science Officer of Global External Research & Development, Oncology at Eli Lilly To Give a Keynote Presentation on “Partnering with Lilly Oncology: Current Priorities, NYC Innovation Hub Model & Possible Future States” at the Novel Cancer Therapeutics Summit 2014...
27 May 2014 | By Daiichi Sankyo
Dainippon Sumitomo Pharma Co., Ltd. and Daiichi Sankyo Co., Ltd. announced that they have entered into a license agreement for the commercialization of lurasidone hydrochloride...
23 May 2014 | By Pfizer
Pfizer Inc. announced detailed results from the Oral treatment Psoriasis Trial Retreatment study, a Phase 3 study investigating tofacitinib for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis...
22 May 2014 | By Daiichi Sankyo
Sanford-Burnham Medical Research Institute and Daiichi Sankyo Co., Ltd. announced they have entered into a three-year comprehensive alliance to develop first-in-class therapeutics for the treatment of cardiovascular-metabolic diseases...
19 May 2014 | By PerkinElmer
The Opera Phenix™ delivers uncompromising speed and sensitivity, accelerating the understanding of disease and discovery of new and more effective treatment therapies...
19 May 2014 | By Eureka Conferences
Eureka Conferences is pleased to announce Drug Discovery & Therapy World Congress 2014, scheduled to be held from 16th - 19th June, 2014...
19 May 2014 | By Boehringer Ingelheim
Results from the Phase III INPULSIS™ trials, published online in the New England Journal of Medicine, show nintedanib* significantly slowed disease progression in patients with idiopathic pulmonary fibrosis...
16 May 2014 | By Oxford Global Conferences
Registration is now closing for Oxford Global’s Pharma R&D Europe Series, the leading pharmaceutical discussion forum in Europe...
16 May 2014 | By Pfizer
The American College of Physicians announced a new initiative designed to increase adult immunization rates by assisting physicians and other health care providers in strongly recommending appropriate vaccination...
16 May 2014 | By Abbott
Abbott enhances its position in fast-growing Latin American market, more than doubling its branded generics pharmaceutical sales and presence in the region...
13 May 2014 | By GlaxoSmithKline
GlaxoSmithKline announced headline results from its second phase III study with darapladib, SOLID-TIMI 52, evaluating the efficacy of its investigational Lp-PLA2 inhibitor in adults following an acute coronary syndrome...
13 May 2014 | By Johnson & Johnson
Latest innovative collaboration from the Janssen Global Public Health group and significant contribution to Johnson & Johnson’s wider efforts to improve public health worldwide...
